Alzamend Neuro 8-K: Executive Compensation Arrangements Updated

TL;DR

**Alzamend Neuro just updated executive pay, watch for details on impact.**

AI Summary

Alzamend Neuro, Inc. filed an 8-K on January 5, 2024, reporting changes in its executive compensation arrangements. This filing indicates potential adjustments to how the company incentivizes its leadership, which could impact future financial performance and shareholder value. Investors should monitor subsequent filings for details on specific compensation changes and their potential effects on the company's cash flow and operational expenses.

Why It Matters

Changes in executive compensation can influence management's motivation and the company's financial health, directly affecting shareholder returns.

Risk Assessment

Risk Level: medium — Changes in executive compensation can be a double-edged sword, potentially motivating leadership but also increasing expenses if not structured wisely.

Analyst Insight

Investors should closely monitor future filings for specific details regarding the new compensatory arrangements, as these will clarify the financial impact on Alzamend Neuro, Inc. and its leadership incentives.

Key Players & Entities

• Alzamend Neuro, Inc. (company) — the registrant filing the 8-K
• January 5, 2024 (date) — date of earliest event reported and filing date
• 001-40483 (other) — Commission File Number for Alzamend Neuro, Inc.
• 81-1822909 (other) — I.R.S. Employer Identification No. for Alzamend Neuro, Inc.

FAQ

Key Financial Figures

• $0.0001 — nge on which registered Common Stock, $0.0001 par value ALZN The Nasdaq Capital M

Filing Documents

• o152408k.htm (8-K) — 26KB
• 0001214659-24-000330.txt ( ) — 199KB
• alzn-20240105.xsd (EX-101.SCH) — 3KB
• alzn-20240105_lab.xml (EX-101.LAB) — 33KB
• alzn-20240105_pre.xml (EX-101.PRE) — 22KB
• o152408k_htm.xml (XML) — 3KB

02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Effective January 4, 2024, Alzamend Neuro, Inc., a Delaware corporation (the " Company "), appointed Milton C. Ault, III as a director and Vice Chairman of its board of directors (the " Board "). Mr. Ault, 54, founded the Company, a biotechnology firm dedicated to researching and finding treatments, prevention methods, and cures for Alzheimer's Disease, on February 25, 2016. He then served as the Company's Chairman until its initial public offering, at which point he transitioned to the role of Chairman Emeritus and consultant until his appointment to its Board and as Vice Chairman. As of the date of Mr. Ault's appointment, his consulting agreement, including the compensation thereunder, was terminated. Mr. Ault currently holds the position of Executive Chairman at Ault Alliance, Inc., a diversified holding company listed on the NYSE American (the " NYSE ") and Chairman of the Board at Ault Disruptive Technologies Corporation, a Special Purpose Acquisition Company listed on the NYSE. On December 29, 2023, Mr. Ault was appointed as a Director of RiskOn International, Inc., a diversified holding company listed on the Nasdaq Stock Market (the " Nasdaq "). Since January 2011, Mr. Ault has been the Vice President of Business Development at MCKEA Holdings, LLC, a family office. He has also been the Chairman of Avalanche International Corp., a publicly traded Nevada company categorized as a voluntary filer (not required to file periodic reports) since September 2014.Since December 2015, Mr. Ault has held the positions of Chairman and Chief Executive Officer at Ault & Company, Inc., a Delaware holding company. In April 2023, Mr. Ault was appointed as the Executive Chairman of the board of directors of the Singing Machine Company, Inc., a company listed on the Nasdaq. There are no family relationships between Mr. Aul

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits: Exhibit No. Description 101 Pursuant to Rule 406 of Regulation S-T, the cover page is formatted in Inline XBRL (Inline eXtensible Business Reporting Language). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document and included in Exhibit 101). -2- SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ALZAMEND NEURO, INC. Dated: January 5, 2024 /s/ Henry Nisser Henry Nisser Executive Vice President and General Counsel -3-

View Full Filing

View this 8-K filing on SEC EDGAR